微流控技术在过继细胞免疫治疗中的应用研究进展  

Research progress in application of microfluidic technology in adoptive cell immunotherapy

作　　者：雷云昊 雷永刚 LEI Yunhao;LEI Yonggang(College of Medical Imaging,Dalian Medical University,Dalian 116000,China)

机构地区：[1]大连医科大学医学影像学院,辽宁大连116000 [2]渭南市中心医院泌尿外科,陕西渭南714000

出　　处：《陕西医学杂志》2024年第5期718-720,F0003,共4页Shaanxi Medical Journal

摘　　要：过继细胞疗法(ACT)是一种个体化疗法,通过采集患者自身或供体的T细胞,在体外进行基因增强后重新引入患者体内,以对抗特定的癌细胞或感染因子。然而,ACT存在许多的局限性,如多步骤耗时且成本高昂等。微流控技术(MT)是以微观通道流动为基础,借助微加工技术制造的微流体芯片和微阀门系统进行分析和操作的技术。微流控平台具有集成度高、效率高、高通量、样品需求低等优点,能够有效简化ACT制备步骤,降低生产成本,探索药物开发过程中的多种因素,以及模拟肿瘤微环境。现对MT在ACT疗法中的细胞分选、细胞增殖和临床前测定及药物评估方面以及在其他肿瘤免疫治疗中的应用进行综述。Adoptive cell therapy(ACT)is a individualized therapy that uses T cells from a patient's own body or a donor to be genetically enhanced in vitro and then reintroduced into the patient to fight specific cancer cells or infectious agents.However,ACT has many limitations,such as multi-step time-consuming and costly.Microfluidic technology(MT)is a technology that analyzes and operates microfluidic chips and microvalve systems manufactured with the help of microfabrication technology based on microchannel flow.The microfluidic platform has the advantages of high integration,high efficiency,high throughput,and low sample requirements,which can effectively simplify ACT preparation steps,reduce production costs,explore multiple factors in the drug development process,and simulate the tumor microenvironment.This article reviews the application of MT in cell sorting,cell proliferation and preclinical assay and drug evaluation in ACT therapy,as well as its application in other tumor immunotherapies.

关 键 词：过继细胞疗法 微流控技术 免疫治疗 细胞分选 细胞增殖 临床前检测 药物评估 

分 类 号：R392.9[医药卫生—免疫学]